Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries
单位：[1]Mackay Mem Hosp, Ctr Canc, Taipei, Taiwan[2]Natl Univ Singapore, Singapore 117548, Singapore[3]Catholic Univ Korea, St Vincents Hosp, Suwon, South Korea[4]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Ctr Canc, Wuhan 430074, Peoples R China肿瘤科华中科技大学同济医学院附属同济医院[5]Kyungpook Natl Univ, Med Ctr, Taegu, South Korea[6]Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea[7]OptumInsight Inc, Stockholm, Sweden[8]Merck Sharp & Dohme Ltd, Global Med Affairs, Seoul, South Korea[9]Merck Sharp & Dohme Ltd, Global Med Affairs, Singapore, Singapore[10]Merck Res Labs, Global Hlth Outcomes, Whitehouse Stn, NJ USA[11]Univ Adelaide, Fac Hlth Sci, Adelaide, SA, Australia
This paper describes the incidence of chemotherapy-induced nausea and vomiting (CINV) after highly or moderately emetogenic chemotherapy (HEC or MEC) for cancer in six Asia Pacific countries. Sequential adult patients na < ve to chemotherapy and scheduled to receive at least two cycles of single-day HEC or MEC were enrolled in this prospective observational study. Patients completed the Multinational Association of Supportive Care in Cancer (MASCC) Antiemesis Tool on post-chemotherapy days 2 and 6 to record acute-phase (first 24 h) and delayed-phase (days 2-5) CINV. There were 648 evaluable patients (318 HEC, 330 MEC) from Australia (n = 74), China (153), India (88), Singapore (57), South Korea (151), and Taiwan (125). Mean (SD) patient age was 56 (12) and 58 % of patients were women; the most common primary cancers were breast (27 %), lung (22 %), and colon (20 %). Overall in cycle 1, complete response (no emesis or rescue antiemetics) was recorded by 69 % (95 % confidence interval (CI), 66-73) of all evaluable patients, with country percentages ranging from 55 to 78 % (p < 0.001). After HEC, no emesis was recorded by 75 % and no nausea by 38 % of patients. After MEC, 80 % had no emesis and 50 % no nausea. Acute-phase CINV was better controlled than delayed-phase CINV, and the control of nausea was the lowest of any CINV measure in all phases. In a CINV perception survey, physicians tended to overestimate emesis rate and underestimate nausea rate. CINV remains a substantial problem, and country-specific information about CINV can be useful in developing strategies to improve outcomes for patients undergoing chemotherapy.
基金：
Merck Co., Inc.; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2014]版：
大类|3 区医学
小类|2 区卫生保健与服务2 区康复医学4 区肿瘤学
最新[2025]版：
大类|3 区医学
小类|2 区康复医学3 区卫生保健与服务3 区肿瘤学
JCR分区：
出版当年[2013]版：
Q1REHABILITATIONQ2HEALTH CARE SCIENCES & SERVICESQ3ONCOLOGY
最新[2023]版：
Q1REHABILITATIONQ2HEALTH CARE SCIENCES & SERVICESQ2ONCOLOGY
第一作者单位：[1]Mackay Mem Hosp, Ctr Canc, Taipei, Taiwan
通讯作者：
推荐引用方式(GB/T 7714)：
Hsieh Ruey Kuen,Chan Alexandre,Kim Hoon-Kyo,et al.Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries[J].SUPPORTIVE CARE IN CANCER.2015,23(1):263-272.doi:10.1007/s00520-014-2373-2.
APA：
Hsieh, Ruey Kuen,Chan, Alexandre,Kim, Hoon-Kyo,Yu, Shiying,Kim, Jong Gwang...&Keefe, Dorothy M. K..(2015).Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries.SUPPORTIVE CARE IN CANCER,23,(1)
MLA：
Hsieh, Ruey Kuen,et al."Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries".SUPPORTIVE CARE IN CANCER 23..1(2015):263-272
